MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/tp.0000000000005897

Медицинская библиотека · Transplantation · 2026

Study on the Antirejection Effects of the Dual ICOS and CD28 Antagonist Acazicolcept (ALPN-101) in Mouse Skin and Heart Transplantation Models.

Guo Leigang, Ma Xiaojingnan, Ma Tingting, Yang Zhen, Li Lin, Liu Yaojuan, Wang Jianxi, Zhan Panpan, Shen Zhongyang

СтатьяПеревод в очереди

Аннотация

BACKGROUND

T cell-mediated rejection significantly constrains the success of organ transplantation. T-cell activation relies on the complementary CD28 and ICOS costimulatory pathways. Thus, this research assessed a new dual CD28/ICOS antagonist, acazicolcept, in rigorous allogeneic transplantation models.

METHODS

Mouse models for allogeneic skin transplantation and abdominal heterotopic heart transplantation were developed. Recipients received acazicolcept, PBS, FK506, or single-pathway antagonists (belatacept or prezalumab). Graft viability, histopathological analysis, and T-cell infiltration were evaluated. Flow cytometry assessed spleen and blood lymphocyte subsets and costimulatory molecules. Donor-specific antibodies and graft C4d deposition were assessed to evaluate humoral responses.

RESULTS

Acazicolcept significantly extended the median survival time of skin and heart allografts to 31 d and 42.5 d, respectively, substantially surpassing other groups and mitigated histopathological damage. Mechanistic investigations demonstrated that the drug simultaneously downregulated the surface expression of CD28 and ICOS on T cells; effectively inhibited the development of effector memory T cells (Tem); and reduced the expression of PD-1 and CD69, reflecting a profound attenuation of early T-cell activation. Moreover, acazicolcept markedly inhibited humoral immune responses, as demonstrated by diminished C4d deposition in grafts and lowered levels of donor-specific antibody-IgG/IgM in peripheral blood.

CONCLUSIONS

Acazicolcept exhibits robust, superior antirejection efficacy compared with single-pathway blockades by concurrently inhibiting CD28 and ICOS signals. This dual mechanism effectively suppresses T-cell activation, effector memory differentiation, and the subsequent antibody-mediated response, offering a robust preclinical justification for its clinical advancement in solid organ transplantation.

Для цитирования: Guo Leigang, Ma Xiaojingnan, Ma Tingting, Yang Zhen, Li Lin, Liu Yaojuan, Wang Jianxi, Zhan Panpan, Shen Zhongyang. Study on the Antirejection Effects of the Dual ICOS and CD28 Antagonist Acazicolcept (ALPN-101) in Mouse Skin and Heart Transplantation Models.. Transplantation. 2026. DOI: 10.1097/tp.0000000000005897.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.